Status:
RECRUITING
No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Lead Sponsor:
Kafrelsheikh University
Conditions:
No-Reflow
STEMI
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
Detailed Description
ST-segment-elevation myocardial infarction (STEMI) is most commonly caused by rupture or erosion of an atherosclerotic plaque, resulting in acute occlusion of the coronary artery, and the preferred re...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old.
- Both sexes.
- Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain \>30 minutes with ST-segment elevation of \>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.
Exclusion
- Treatment with thrombolytic drugs in the previous 24 hours.
- Known malignancy.
- Thrombocytopenia.
- End-stage liver disease.
- Cardiogenic shock.
- Renal failure with glomerular filtration\<30 ml/min.
- Contraindication for the use of tirofiban.
Key Trial Info
Start Date :
May 12 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06966674
Start Date
May 12 2025
End Date
October 1 2025
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kafrelsheikh University
Kafr ash Shaykh, Kafrelsheikh, Egypt, 33516